abicipar pegol
Recombinant proteinexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01397409)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
Vascular endothelial growth factor A inhibitor
- Vascular endothelial growth factor CSupplementation
VEGFC supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297684 ↗
Also known as
- abicipar pegol
- abicipar pegol
- agn-150998
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03539549 | Phase 2 | May 23, 2018 | Allergan |
| NCT03335852 | Phase 1 | Nov 28, 2017 | Allergan |
| NCT02859766 | Phase 1 | Dec 1, 2016 | Allergan |
| NCT02462486 | Phase 3 | Jun 25, 2015 | Allergan |
| NCT02462928 | Phase 3 | Jun 25, 2015 | Allergan |
| NCT02181504 | Phase 2 | Sep 1, 2014 | Allergan |
| NCT02186119 | Phase 2 | Jul 1, 2014 | Allergan |
| NCT02181517 | Phase 2 | Jul 1, 2014 | Allergan |
| NCT01397409 | Phase 2 | Sep 1, 2011 | Allergan |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 9 | 9 | 3 | 2011 |
1 organizations
Page 1 / 1